Ionis Pharmaceuticals
Pfizer sees no way forward for Ionis-partnered vupanorsen
Phil Taylor
antisense drugs, cardiovascular, Ionis Pharmaceuticals, Pfizer, Regeneron
0 Comment
Biogen looks beyond Spinraza in SMA with Ionis deal
Phil Taylor
Biogen, Evrysdi, Ionis Pharmaceuticals, Novartis, rare disease, Roche, spinal muscular atrophy, Spinraza, Zolgensma
0 Comment
AZ gets closer to Ionis, licensing amyloidosis drug in $3.6bn deal
Phil Taylor
Alnylam Pharmaceuticals, antisense oligonucleotides, AstraZeneca, ATTR amyloidosis, Ionis Pharmaceuticals, partnering, Pfizer
0 Comment
Could safety scupper Ionis, Pfizer’s cholesterol drug vupanorsen?
Phil Taylor
antisense drugs, cardiovascular, cholesterol, evinacumab, Ionis Pharmaceuticals, Pfizer, Regeneron
0 Comment
NICE relents and okays Akcea’s rare disease drug Waylivra for NHS use
Phil Taylor
Akcea Therapeutics, antisense drugs, Familial Chylomicronaemia Syndrome, Ionis Pharmaceuticals, NHS, NICE, rare disease
0 Comment
GSK takes option to license hepatitis B RNA drugs from Ionis
Richard Staines
GlaxoSmithKline, Ionis Pharmaceuticals, R&D
0 Comment
Ionis’ FCS drug approved in EU, launch due in Germany
Richard Staines
Akcea, Ionis Pharmaceuticals, market access, ultra-rare diseases
0 Comment
Ionis and Roche to develop RNAi AMD drug in $760m deal
Joy Persaud
Ionis Pharmaceuticals, ophthalmology, Roche, wet AMD
0 Comment